Auna S.A. (AUNA)

Auna S.A. is a mixed picture: a deeply discounted but highly leveraged Latin American hospital operator. Trailing metrics are extreme in both directions — roughly 6x EV/EBITDA and a ~37.5% FCF yield against ~4.2x net debt/EBITDA, ~1.6x interest coverage and an Altman Z-Score of ~0.96 (distress zone). FY2025 was flat with refinancing-related costs, but H1 2026 shows revenue up ~13% YoY, operating cash flow of S/441M (versus S/243M for all of FY2025) and improving leverage at 3.6x. SEC filings show no going-concern warnings or covenant breaches and long-dated 2032 secured notes. The stock is cheap for structural reasons — heavy interest burden, FX and political risk, concentrated dual-class control — but the cash-based run-rate argues against a pure distressed label. Watchlist stance.

No catalyst clears the 30-day actionability screen — the Q2 print (announced via Business Wire, 2026-08-18) was a miss the tape sold but sits 28 days trailing, and the inaugural Investor Day (2026-10-22) lands 36 days out — while the item-level sentiment delta reads determinate deterioration on moderate confidence after two consecutive quarterly EPS misses and a two-week editorial silence. Red-Flag Screen: no severe or moderate flags, no cap applied.

AUNA is consolidating in a $5.01–$5.43 band after its August earnings gap, holding above all three SMAs (close 5.23 vs SMA20 5.22 / SMA50 5.20 / SMA200 5.06) with the EMA9/EMA21 stack below price — a mildly constructive frame. Momentum is neutral rather than confirming: RSI14 51.27, Williams %R −47.62, MACD line −0.01 sitting just under a flat signal (histogram −0.01), and ADX 21.81 shows no directional strength. Volume is chronically thin (20-day average dollar volume ≈ $0.81M). Mixed chart: trend frame mildly bullish, momentum frame neutral — score 3.